A preliminary randomized trial of the safety, tolerability, and clinical effects of hemp-derived cannabidiol in alcohol use disorder

Bibliographic Data

ID15517709
AuthorsRaeghan L Mueller (0000-0001-5249-1532, University of Colorado Anschutz Medical Campus, corresponding author), Judith Hooper (0009-0002-1350-3881, University of Colorado Anschutz Medical Campus), Jake F Hooper, Jarrod M Ellingson (0000-0001-9932-2656, University of Colorado Anschutz Medical Campus), Aviva K Olsavsky (0000-0002-7779-1491, University of Colorado Anschutz Medical Campus), Rachael Rzasa-Lynn (University of Colorado Anschutz Medical Campus), Angela D Bryan (0000-0002-6019-3380, University of Colorado Boulder), L Cinnamon Bidwell (0000-0001-6762-7586, University of Colorado Boulder), Kent E Hutchison (0000-0002-4805-9277, University of Colorado Anschutz Medical Campus)
Year2025
Volume16
Pages1516351-1516351
Publication date2025-04-28
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2025.1516351
PMID40357520
OpenAlexW4409866419
LanguageEN
References cited35

In this pilot study, safety profiles fsCBD and bsCBD were similar, and fsCBD was associated with a greater reduction in craving and AUD symptoms relative to both bsCBD and placebo. Future studies with larger sample sizes will be necessary to replicate and extend these findings by addressing the question of whether a small amount of THC may work synergistically with CBD

Adverse effect · Alcohol · Alcohol dependence · Alcohol use disorder · Cannabidiol · Cannabis · Clinical trial · Psychiatry · Randomized controlled trial · Tolerability · Alcohol Consumption and Health Effects · Cannabis and Cannabinoid Research · Chemistry · Medicine · Psychology · Substance Abuse Treatment and Outcomes · Internal Medicine · Pharmacology

Tools

Open DOIOpen Access